Expert Guidance on the Expanding Role of Immunotherapy in HNSCC: A Live Workshop Series

Expert Guidance on the Expanding Role of Immunotherapy in HNSCC: A Live Workshop Series

Thursday, March 12, 2020 in Lawrenceville, GA
Live Meeting -- Northside Hospital Gwinnett, 12:00 PM ET
Gwinnett, Building 631, Suite 220 Cancer Community Room

Agenda

  • Welcome
  • Rationale for Immune Checkpoint Inhibitors and Optimizing Treatments for Recurrent or Metastatic HNSCC
  • Practical Guidance for Clinical Integration of Immune Checkpoint Inhibitors
  • Future Directions for Immuno-Oncology in HNSCC
  • Closing remarks

Faculty

Faculty
Nabil Saba, MD

Professor, Hematology and Medical Oncology
Professor of Otolaryngology
Director, 
Head and Neck Oncology Program
Winship Cancer Institute of Emory University
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating immunotherapy into the treatment of patients with head and neck cancer.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers and their patients with HNSCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Gain insight on the role of the immune system and immune escape in HNSCC, along with the mechanisms of action of different immune modulatory agents
  • Plan therapeutic strategies for patients with recurrent or metastatic HNSCC that has progressed on or after platinum-containing chemotherapy
  • Evaluate the latest science and clinical trial results of immune checkpoint inhibitors in adjuvant and neoadjuvant settings and alone or in combination with radiotherapy or biotherapy across all indications
  • Identify patients that would benefit from immunotherapy based on optimal assessment of predictive biomarkers
  • Manage immune-related toxicities associated with immune checkpoint inhibitors in patients with HNSCC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-044-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.